Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).
RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.
The user has been using oral minoxidil 2.5mg and finasteride 1mg for 3 months and is unsure if they are experiencing hair regrowth or if it's an illusion. Some responses suggest it is regrowth, while others think it's an illusion due to angles and lighting.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, RU58841, and TB-500 Thymosin Beta-4. It critiques the credibility of biohacking claims.
Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.
RU58841 is discussed as a hair loss treatment, with users considering lower doses like 2.5% to reduce costs. Some users suggest that if already blocking DHT, lower doses might still be effective unless there's high sensitivity to DHT.
The conversation discusses the effectiveness of RU58841 and pyrilutamide for hair loss treatment. It seeks personal success or failure stories and scientific data on these treatments.
A user claims a product can treat alopecia, but others are skeptical, calling it a scam due to lack of evidence and transparency. The product is said to inhibit Type II 5-αr by 22.9%, but is considered weaker than existing DHT blockers.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
RU58841 is discussed as a treatment that stops scalp itching when used with finasteride or dutasteride. The user is considering trying RU58841 due to persistent itching despite using the "big 3" treatments.
RU58841 is discussed as a potential treatment for acne and hair loss, with users debating its effectiveness and safety compared to other treatments like finasteride, minoxidil, and dutasteride. Concerns about RU58841's side effects and lack of clinical trials are raised, while some users share their personal experiences and routines involving RU58841 for hair loss.
GeneTherica is discussed as a source for RU58841, with ordering possible via WhatsApp. The conversation focuses on the legitimacy of this supplier for hair loss treatment.
The drugs RU-58841, Pyrilutamide (KX-826), Apalutamide, Enzalutamide, and Darolutamide, which are nonsteroidal antiandrogens (NSAA), potentially impacting male fertility. Pyrilutamide, similar to Enzalutamide, may have reversible effects on fertility.
Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.
The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.
Post Finasteride Syndrome (PFS) may result from epigenetic changes and gut microbiota alterations. Supplementing with Allopregnanolone might protect against these adverse effects.
Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.
The conversation discusses using daily microneedling at 0.25mm and red light therapy to enhance hair regrowth, especially when traditional treatments like finasteride and minoxidil become less effective. The combination is said to improve hair density and thickness, with red light therapy being more cosmetic, while microneedling is essential for challenging areas.
Discouragement regarding Pyrilutamide, a drug in development for hair loss, and the potential side effects of Finasteride. People discussed anecdotal experiences with Pyrilutamide as well as suggestions to wait out Phase 3 trials before making any conclusions.
A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.
The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.
Alfatradiol helps reduce hair shedding and itching, and is effective for mild hair loss. Users combine it with treatments like fluridil, minoxidil, and sometimes consider finasteride.
Low-level laser therapy (LLLT) is discussed as a supplementary treatment for hair loss, with users recommending brands like LaserCap, Ideatherapy, Capillus Pro, and iRestore Pro. Users suggest combining LLLT with treatments like minoxidil and finasteride for better results.
The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.
A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.